Johnson & Johnson Concludes Work on Addex's ADX71149 Epilepsy Treatment
Thursday, 18 July 2024, 21:52
Johnson & Johnson Ends Development of ADX71149
Johnson & Johnson (JNJ) has reportedly made the decision to cease its development program for the epilepsy drug candidate ADX71149, which was being developed in partnership with Addex (ADXN). The decision signifies a substantial shift in J&J's research focus.
Implications for the Pharmaceutical Industry
- Challenges in drug development
- Impact on epilepsy treatment options
- Future strategies of Addex
This withdrawal not only affects J&J but also poses questions about the future trajectory of Addex in the competitive pharmaceutical landscape.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.